DYRK3: A Potential Drug Target for Cancer, Neurodegenerative Diseases and Autoimmune Disorders

Target Name: DYRK3

NCBI ID: G8444

DYRK3

DYRK3: A Potential Drug Target for Cancer, Neurodegenerative Diseases and Autoimmune Disorders

DYRK3 (regulatory erythroid kinase), also known as Drp1 (DNA-binding protein 1), is a protein that plays a crucial role in the regulation of cell proliferation and differentiation. It is a member of the tyrosine kinase family and is localized to the cytoplasm of eukaryotic cells. DYRK3 has been identified as a potential drug target and has been shown to be involved in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

DYRK3 function

DYRK3 is a protein that is involved in the regulation of several cellular processes, including cell growth, differentiation, and apoptosis. It plays a key role in the development and maintenance of normal cellular growth and proliferation. DYRK3 is a transcription factor that can activate or repress the expression of genes involved in cell growth and differentiation. It has been shown to play a role in the regulation of cell cycle progression, including the G1/S transition and the G2/M transition.

DYRK3 has also been shown to play a role in the regulation of apoptosis. DYRK3 has been shown to be involved in the execution of cell apoptosis, which is a natural process that helps to remove damaged or dysfunctional cells from the body. DYRK3 has been shown to play a role in the regulation of apoptosis by activating the B-cell lymphoma 1 (Bcl-2) gene, which is known to encode a protein that can inhibit apoptosis.

DYRK3 and cancer

DYRK3 has been identified as a potential drug target for cancer. Several studies have shown that DYRK3 is involved in the regulation of cancer cell growth and survival. DYRK3 has been shown to play a role in the regulation of the growth factor-induced response of cancer cells, including the inhibition of cell proliferation and the inhibition of angiogenesis.

DYRK3 has also been shown to play a role in the regulation of cell cycle progression, which is a critical process in cancer development. DYRK3 has been shown to play a role in the regulation of the G1/S transition and the G2/M transition, which are critical steps in the cell cycle that are involved in the regulation of cell growth and differentiation.

DYRK3 and neurodegenerative diseases

DYRK3 has also been identified as a potential drug target for neurodegenerative diseases. Several studies have shown that DYRK3 is involved in the regulation of the development and progression of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease.

DYRK3 has been shown to play a role in the regulation of the neurotransmitter dopamine, which is involved in the regulation of mood, motivation, and reward. DYRK3 has been shown to play a role in the regulation of dopamine signaling, including the regulation of the dopamine receptor.

DYRK3 and autoimmune disorders

DYRK3 has also been identified as a potential drug target for autoimmune disorders. Several studies have shown that DYRK3 is involved in the regulation of the development and progression of autoimmune disorders, including rheumatoid arthritis, lupus, and multiple sclerosis.

DYRK3 has been shown to play a role in the regulation of T cell development and function, which is a critical process in the regulation of immune responses. DYRK3 has been shown to play a role in the regulation of the CD4+ T cell response to

Protein Name: Dual Specificity Tyrosine Phosphorylation Regulated Kinase 3

Functions: Dual-specificity protein kinase that promotes disassembly of several types of membraneless organelles during mitosis, such as stress granules, nuclear speckles and pericentriolar material (PubMed:29973724). Dual-specificity tyrosine-regulated kinases (DYRKs) autophosphorylate a critical tyrosine residue in their activation loop and phosphorylate their substrate on serine and threonine residues (PubMed:9748265, PubMed:29634919). Acts as a central dissolvase of membraneless organelles during the G2-to-M transition, after the nuclear-envelope breakdown: acts by mediating phosphorylation of multiple serine and threonine residues in unstructured domains of proteins, such as SRRM1 and PCM1 (PubMed:29973724). Does not mediate disassembly of all membraneless organelles: disassembly of P-body and nucleolus is not regulated by DYRK3 (PubMed:29973724). Dissolution of membraneless organelles at the onset of mitosis is also required to release mitotic regulators, such as ZNF207, from liquid-unmixed organelles where they are sequestered and keep them dissolved during mitosis (PubMed:29973724). Regulates mTORC1 by mediating the dissolution of stress granules: during stressful conditions, DYRK3 partitions from the cytosol to the stress granule, together with mTORC1 components, which prevents mTORC1 signaling (PubMed:23415227). When stress signals are gone, the kinase activity of DYRK3 is required for the dissolution of stress granule and mTORC1 relocation to the cytosol: acts by mediating the phosphorylation of the mTORC1 inhibitor AKT1S1, allowing full reactivation of mTORC1 signaling (PubMed:23415227). Also acts as a negative regulator of EPO-dependent erythropoiesis: may place an upper limit on red cell production during stress erythropoiesis (PubMed:10779429). Inhibits cell death due to cytokine withdrawal in hematopoietic progenitor cells (PubMed:10779429). Promotes cell survival upon genotoxic stress through phosphorylation of SIRT1: this in turn inhibits p53/TP53 activity and apoptosis (PubMed:20167603)

The "DYRK3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DYRK3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets